Evidence
iScience. 2024 Jan 4;27(2):108783. doi: 10.1016/j.isci.2024.108783. eCollection 2024 Feb 16.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD), which has a prevalence of over 25% in adults, encompasses a wide spectrum of liver diseases. Metabolic-dysfunction associated steatotic liver disease (MASLD), the new term for NAFLD, is characterized by steatotic liver disease accompanied by cardiometabolic criteria, showing a strong correlation with metabolic diseases. Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease affecting 4-21% of women of reproductive age. Numerous studies have indicated that NAFLD and PCOS often occur together. However, as MASLD is a new term, there is still a lack of reports describing the effects of MASLD on the development of PCOS. In this review article, we have summarized the complex and multifaceted connections between MASLD and PCOS. Understanding the pathogenesis and treatment methods could not only guide the clinical prevention, diagnosis, and treatment of PCOS in patients with MASLD, but also increase the clinical attention of reproductive doctors to MASLD.
PMID:38292434 | PMC:PMC10825666 | DOI:10.1016/j.isci.2024.108783
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
🌐 365 Days
VR Related Evidence Matrix
